Emmecell receives FDA RMAT designation for EO2002, advancing development of its regenerative cell therapy for corneal ...

The US Food and Drug Administration (FDA) on Thursday launched a new policy framework for regenerative medicine, building off a previous framework from 2005, as part of efforts to bring new cell, stem ...

Organogenesis Holdings Inc. (Nasdaq: ORGO), a leading regenerative medicine company focused on product solutions for the Advanced Wound Care and Surgical and Sports Medicine markets, today announced ...

Dr Tommy Rhee, CEO of RheeGen, outlines how FDA crackdowns have revealed dangerous and unethical tissue sourcing practices: Two decades ago, regenerative medicine started out with an extraordinary ...

The US Food and Drug Administration (FDA) has published three draft guidances on developing cell and gene therapies (CGT) to treat rare diseases, conducting postapproval CGT studies, and using the ...

FDA revamps peptide panel by appointing wellness clinic physicians to advise on pharmacy compounding of seven peptides, including BPC-157 and TB-500.

BrainChild Bio advancing BCB-276 towards BLA submission with a single pivotal Phase 2 trial planned to commence in Q4 2025 SEATTLE & CAMBRIDGE, Mass.--(BUSINESS WIRE)--BrainChild Bio, Inc., a clinical ...

NEEDHAM, Mass., May 28, 2025 (GLOBE NEWSWIRE) -- Candel Therapeutics, Inc. (Candel or the Company) (Nasdaq: CADL), a clinical-stage biopharmaceutical company focused on developing multimodal ...

The U.S. Food and Drug Administration (FDA) issued new draft guidance on Sept. 20, 2025, surrounding expedited programs for regenerative medicine therapies for serious conditions. The draft guidance ...

Torie Bosch is the First Opinion editor at STAT. Paul Knoepfler of the UC Davis School of Medicine has a bit of a hobby: keeping track of stem cell clinics operating in the U.S. He estimates that ...

The FDA granted regenerative medicine advanced therapy designation to EO2002 for the treatment of corneal edema secondary to ...